Joint Department of Physics, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, Surrey, UK.
Nuclear Medicine Department, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.
Clin Oncol (R Coll Radiol). 2021 Feb;33(2):98-105. doi: 10.1016/j.clon.2020.11.028.
Treatments of bone metastases using radionuclides are now well established in oncology. It is also a field that continues to develop. This article reviews the evidence base that led to the approval of strontium-89 and samarium-153 ethylenediaminetetramethylene phophanate (EDTMP) for the palliation of pain from bone metastases, as well as the evidence for the use of radium-223 in metastatic castrate-resistant prostate cancer. Efforts to optimise treatments and improve response rates, either by safely increasing the radiation dose to bone metastases or by combining treatment with non-radiation-based therapies, are discussed. In addition, the development of both alpha- and beta-particle-emitting radiopharmaceuticals designed to target prostate-specific membrane antigen are reviewed.
放射性核素治疗骨转移在肿瘤学中已得到广泛认可，并且这一领域仍在不断发展。本文回顾了导致锶-89 和钐-153 乙二胺四甲撑膦酸盐（EDTMP）获批用于缓解骨转移疼痛的循证医学证据，以及镭-223 治疗转移性去势抵抗性前列腺癌的证据。本文还讨论了通过安全增加骨转移部位的辐射剂量或联合非放射性治疗来优化治疗和提高缓解率的努力。此外，还回顾了旨在针对前列腺特异性膜抗原的α和β粒子放射性药物的开发。
